Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...
Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...
THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
Investor's Business Daily on MSN10d
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1Novo Nordisk stock slipped 1.2% to 69.30. Novo Nordisk Is On A Licensing Spree. This is the second big weight-loss deal from Novo ...
Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity ...
Novo Nordisk has been on the hunt for differentiated ... a drug discovered and developed by Lexicon Pharmaceuticals, the companies announced Friday. LX9851 is an oral small molecule that blocks ...
Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...
Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback